Glucocorticoid

3

Review clinical trials related to Glucocorticoid. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome

This study aims to compare the efficacy and outcomes of perineural injection with 5% dextrose, local ozone and glucocorticoid injection in the management of carpal tunnel syndrome.

Participants needed: 105
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Tanta UniversityUpdated: Mar 27, 2026Locations: 1
Eligibility criteria

Adults aged 18-65 years with a clinical diagnosis of mild to moderate Carpal Tun... [+3]

Patient refusal. [+7]

Status: Recruiting

High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy

The aim is to conduct a randomized controlled trial (RCT) with a high dose arm (1mg/kg) vs a low dose (8mg in total) of steroid (Dexamethasone) given intravenous (IV) after the induction of anesthesia to "High-pain-responders" in patients undergoing VATS lobectomy/segmentectomy. The hypothesis is that a high dose of Dexamethasone can lower pain when coughing in the morning after VATS lobectomy/segmentectomy, in patients scoring as "High-pain-responders" on the Pain-Catastrophizing-Scale

Participants needed: 80
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Rigshospitalet, DenmarkUpdated: Jan 7, 2026Locations: 1
Eligibility criteria

Age ≥ 18 year [+4]

Patients undergoing systemic glucocorticoid or other immunosuppressive therapies... [+9]

Status: Recruiting

Efficacy and Safety of Telitacicept in IgAN

A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.

Participants needed: 118
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Jan 1, 2025Locations: 1
Eligibility criteria

18-70 years old, male or female [+6]

Patients with abnormal laboratory indicators (see study protocol for details). [+13]